Abstract
Background and Aims Queries of electronic health record (EHR) data repositories allow for automated data collection. These techniques have not been utilized in hepatology due to previous inability to capture hepatic encephalopathy (HE) grades, which are inputs for acute-on-chronic liver failure (ACLF) models. Here, we describe a methodology to utilizing EHR data to calculate rolling ACLF scores.
Methods We examined 239 patient-admissions with end-stage liver disease 7/2014-6/2019. We mapped EHR flowsheet data to determine HE grades and calculated two longitudinally updated ACLF scores. We validated HE grades and ACLF diagnoses via chart review; and calculated sensitivity, specificity, and Cohen’s kappa.
Results Of 239 patient-admissions analyzed, 37% women, 46% non-Hispanic White, median age 60 years, median MELD-Na at admission. Of the 239, 7% were diagnosed with NACSELD-ACLF at admission, 27% during the hospitalization, and 9% at discharge. Forty percent diagnosed with CLIF-C-ACLF at admission, 51% during the hospitalization, and 34% at discharge.
From chart review of 51 admissions, we found sensitivities and specificities for any HE (grades 1-4) were 92-97% and 76-95%, respectively; for severe HE (grades 3-4) were 100% and 78-98%, respectively. Cohen’s kappa between flowsheet and chart review HE grades ranged 0.55-0.72. Sensitivities and specificities for NACSELD-ACLF diagnoses were 75-100% and 96-100%, respectively; for CLIF-C-ACLF diagnoses were 91-100% and 96-100%, respectively. We generated approximately 28 unique ACLF scores per patient per admission-day.
Conclusion In this study, we developed an informatics-based methodology for to calculate longitudinally updated ACLF scores. This opens new analytic potentials, such big data methods to develop electronic phenotypes for ACLF patients.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by 5T32DK060414-18 (National Institute of Diabetes and Digestive and Kidney Diseases, Ge) and R01AG059183/K23AG048337 (National Institute on Aging, Lai). The funding agency played no role in the analysis of the data or the preparation of this manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Institutional Review Board at the University of California, San Francisco approved this study.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Abbreviations:
A ACLF, acute-on-chronic liver failure; CDR, clinical data repository; CI, confidence interval; CLIF-C-ACLF, European Association for the Study of Liver – Chronic Liver Failure Consortium – Acute-on-Chronic Liver Failure; CLIF-C-OF, European Association for the Study of Liver – Chronic Liver Failure Consortium – Organ Failures; CVVH, continuous venovenous hemofiltration; CVVHD, continuous venovenous hemodialysis; EF-CLIF, European Foundation for the Study of Chronic Liver Failure; EHR, electronic health record; ESLD, end-stage liver disease; FiO2, oxygen fraction; FrAILT, Multi-Center Functional Assessment in Liver Transplantation Study; GCS, Glasgow Coma Score; HE, hepatic encephalopathy; ICD, International Classification of Diseases; IQR, interquartile range; INR, international normalized ratio; LFI, Liver Frailty Index; MELD, Model for End-Stage Liver Disease; MELD-Na, Model for End-Stage Liver Disease-Sodium; NACSELD, North American Consortium for the Study of End-Stage Liver Disease; NACSELD-ACLF Score, North American Consortium for the Study of End-Stage Liver Disease – Acute-on-Chronic Liver Failure Score; NACSELD-OF, North American Consortium for the Study of End-Stage Liver Disease – Organ Failures; OMOP, Observational Medical Outcomes Partnership; P/F Ratio, partial pressure to fraction of oxygen ratio; RRT, renal replacement therapy; SpO2, oxygen saturation; SQL, Structured Query Language; WHC, West-Haven Criteria;
Financial Support: This study was funded by 5T32DK060414-18 (National Institute of Diabetes and Digestive and Kidney Diseases, Ge) and R01AG059183/K23AG048337 (National Institute on Aging, Lai). The funding agency played no role in the analysis of the data or the preparation of this manuscript.
Conflicts of Interest: The authors have no conflicts of interest to declare.
Writing Assistance: None.
Data Availability
The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.
